Hyderabad Stories
Hyderabad Stories
Public record · updated
Satish-Reddy
PIONEERHEALTH

Kallam Satish Reddy

Chairman, Dr. Reddy’s Laboratories

Kallam Satish Reddy is a business executive and the current Chairman of Dr. Reddy’s Laboratories. He joined Dr. Reddy’s in 1993 as Executive Director and later was promoted to the role of Managing Director in 1997. He is also a trustee of the Naandi Foundation, which works in the areas that empower the society.

As published on Hyderabad Stories, 30 Nov 2020 · not re-verified

Master's in Chemistry
Education
Purdue University
Alma Mater
Pharmaceutical company
Industry
STORIES & COVERAGE

Related News

  1. Times of India

    Hyderabad-based Divi’s Labs second pharma company with Rs 1 lakh crore market capitalization

    City-based Divi’s Laboratories on Thursday became the second pharma player in the country, after Sun Pharma, to enter the elite league of companies with a market capitalization of Rs 1 lakh crore or more.

  2. Telangana Today

    Belgium forging ties with Hyderabad

    Belgium is strengthening its ties with Hyderabad, India’s largest life sciences hub, to help supply vaccines and drugs to global markets, particularly to the Europe region.

  3. Economic Times

    Stock market update: Nifty Pharma index jumps nearly 3%; Dr Reddy's Lab climbs 4%

    Nifty Pharma index was trading with losses at 11:48 AM (IST) on Monday. Shares of Dr.

  4. The Hindu

    Dr Reddy's Laboratories launches succinylcholine chloride injection in US

    Dr. Reddy’s Laboratories Ltd has launched Succinylcholine Chloride injection, a therapeutic equivalent generic version of Quelicin (Succinylcholine Chloride) injection, in the US market.

  5. Telangana Today

    Dr Reddy’s, RDIF receive approval to conduct clinical trial for Sputnik V vaccine

    Hyderabad-based pharmaceuticals company Dr Reddy’s Laboratories and Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India.

Provenance

Sources

  1. 01Hyderabad Stories profilehyderabadstories.com